Peter Lawson Analyst PerformanceUS Biotech Equity Analyst - Managing Director at BarclaysPeter Lawson is a stock analyst at Barclays in the medical sector, covering 29 publicly traded companies. Over the past year, Peter Lawson has issued 13 stock ratings, including buy and hold recommendations. While full access to Peter Lawson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Peter Lawson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings58 Last 11 YearsBuy Recommendations70.69% 41 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution58RatingsDistribution of strong buy, buy, hold, and sell ratings by Peter Lawson.RatingPercentageCount Strong Buy0.0%0 ratings Buy70.7%41 ratings Hold25.9%15 ratings Sell3.4%2 ratingsOut of 58 total stock ratings issued by Peter Lawson at Barclays, the majority (70.7%) have been Buy recommendations, followed by 25.9% Hold and 3.4% Sell.Best & Worst CallsBest Call0000.0%RCUSApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%VSTMAug 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ93.1% of companies on NASDAQ27 companiesNYSE3.4% of companies on NYSE1 companyNYSEAMERICAN3.4% of companies on NYSEAMERICAN1 companyPeter Lawson, an analyst at Barclays, currently covers 29 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical29 companies100.0%Peter Lawson of Barclays specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE22 companies75.9%MED - DRUGS3 companies10.3%MED PRODUCTS2 companies6.9%MEDICAL INFO SYS1 company3.4%BIOTECHNOLOGY1 company3.4% Peter Lawson's Ratings History at Barclays Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsONCBeOne Medicines5/7/2026Boost Price Target$313.32$409.00Overweight$0.0000.00% ROIONCBeOne Medicines2/27/2026Boost Price Target$316.47$405.00Overweight$0.0000.00% ROIONCBeOne Medicines2/4/2026Boost Price Target$346.38$394.00Overweight$0.0000.00% ROIINCYIncyte11/24/2025Boost Price Target$102.06$115.00Overweight$0.0000.00% ROISNDXSyndax Pharmaceuticals11/4/2025Boost Price Target$13.76$22.00Overweight$0.0000.00% ROIINCYIncyte10/29/2025Boost Price Target$91.65$101.00Overweight$0.0000.00% ROIONCBeOne Medicines9/18/2025Initiated Coverage$332.20$385.00Overweight$0.0000.00% ROIIDYAIDEAYA Biosciences9/4/2025Initiated Coverage$25.76$40.00Overweight$0.0000.00% ROIIDYAIDEAYA Biosciences9/4/2025Initiated Coverage$25.83$40.00Overweight$0.0000.00% ROISDGRSchrodinger8/14/2025Initiated Coverage$19.84$25.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. SDGRSchrodinger8/14/2025Initiated Coverage$19.45$25.00Overweight$0.0000.00% ROIREPLReplimune Group7/23/2025Downgrade$2.81$3.00Equal Weight$0.0000.00% ROIEXELExelixis7/10/2025Boost Price Target$44.75$40.00Equal Weight$0.0000.00% ROIMGNXMacroGenics5/14/2025Reiterated Rating$1.54$3.00Overweight$0.0000.00% ROIFATEFate Therapeutics5/14/2025Lower Price Target$0.98$2.00Overweight$0.0000.00% ROIADAPAdaptimmune Therapeutics5/14/2025Lower Price Target$0.28$0.46Underweight$0.0000.00% ROIKPTIKaryopharm Therapeutics5/13/2025Boost Price Target$5.30$10.00Overweight$0.0000.00% ROIIOVAIovance Biotherapeutics5/12/2025Lower Price Target$1.81$4.00Overweight$0.0000.00% ROIXNCRXencor5/8/2025Lower Price Target$8.98$6.00Underweight$00.0000.00% ROIKURAKura Oncology5/2/2025Lower Price Target$6.34$11.00Overweight$0.0000.00% ROIARVNArvinas5/2/2025Lower Price Target$7.08$16.00Overweight$00.0000.00% ROIBCYCBicycle Therapeutics5/1/2025Lower Price Target$9.08$15.00Overweight$0.0000.00% ROISWTXSpringWorks Therapeutics4/28/2025Reiterated Rating$46.18$47.00Equal Weight$0.0000.00% ROIRCUSArcus Biosciences4/23/2025Lower Price Target$8.11$14.00Overweight$00.0000.00% ROIIOVAIovance Biotherapeutics4/14/2025Lower Price Target$3.43$5.00Overweight$0.0000.00% ROIBMEABiomea Fusion4/2/2025Lower Price Target$2.05$3.00Equal Weight$0.0000.00% ROITCRXTScan Therapeutics3/7/2025Lower Price Target$2.08$3.00Overweight$0.0000.00% ROIEXELExelixis2/13/2025Boost Price Target$33.98$29.00Equal Weight$00.0000.00% ROIARVNArvinas2/3/2025Lower Price Target$17.61$32.00Overweight$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
